A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat

Abroad (travel likely)RecruitingPHASE1

Conditions

Fatty Liver Disease

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Altasciences Clinical Company, Inc, Montreal, Quebec, Canada

Study leads

Clinical Transparency' (dept. 2834)
Study Director
Novo Nordisk A/S

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD

Non-Alcoholic Fatty Liver Disease

Abroad (travel likely)Recruiting

Québec, Canada

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

Non-alcoholic Fatty Liver Disease

Abroad (travel likely)RecruitingPHASE3

Arcadia, United States · Covina, United States

Quantifying Hepatic Mitochondrial Fluxes in Humans

Non-Alcoholic Fatty Liver Disease · Type 2 Diabetes · Mitochondrial Metabolism Disorders

Abroad (travel likely)RecruitingPHASE4

San Antonio, United States · San Antonio, United States

NAC- NAFLD And Cushing

Cushing Syndrome · Fatty Liver Disease

Abroad (travel likely)Recruiting

Angers, France · Bordeaux, France